Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Multiple Myeloma 2Neoplasms, Plasma Cell 1Myelodysplastic Syndromes 1Hematologic Diseases 1Bone Marrow Neoplasms 1Bone Marrow Diseases 1

Interventions

Cyclophosphamide 110fludarabine phosphate 106Busulfan 84Azacitidine 73Peripheral Blood Stem Cell Transplantation 64Mycophenolic Acid 64Antilymphocyte Serum 64Cytarabine 63Tacrolimus 62fludarabine 61Cyclosporine 56Filgrastim 55Whole-Body Irradiation 52Methotrexate 47Melphalan 42Decitabine 42Radiotherapy 37Clofarabine 29Granulocyte Colony-Stimulating Factor 28Cord Blood Stem Cell Transplantation 28Methylprednisolone 24Etoposide 24thymoglobulin 21Thiotepa 21Stem Cell Transplantation 21sargramostim 19Sirolimus 16Alemtuzumab 15Lenalidomide 13Gemtuzumab 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Myelodysplastic Syndromes × SCIO-469 × Clear all
NCT00113893 2013-11-07

SCIO-469: Open-Label Study for Patients With Myelodysplastic Syndromes.

Scios, Inc.

Phase 2 Completed
62 enrolled
Myeloid

Bone Marrow Diseases, Hematologic Diseases, Myelodysplastic Syndromes, Bone Marrow Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡